Naber, Kurt G.
Wagenlehner, Florian
Kresken, Michael
Cheng, Wendy Y.
Catillon, Maryaline
Duh, Mei Sheng
Yu, Louise
Khanal, Anamika
Mulgirigama, Aruni
Joshi, Ashish V.
Ju, Shinyoung
Mitrani-Gold, Fanny S.
Funding for this research was provided by:
GSK
Article History
Received: 27 October 2022
Accepted: 17 July 2023
First Online: 26 July 2023
Competing interests
: K.G.N. discloses consultancy fees from AdamedPharma, Biomerieux, Bionorica, Eumedica, GSK, Immunotek, OM Pharma, and MIP/Rosen Pharma. F.W. is an advisor of GSK and a principal investigator in a GSK-sponsored study. M.K is a partner and CEO of Antiinfectives Intelligence GmbH, a research organization providing services to pharmaceutical companies. W.Y.C., M.C., M.S.D., L.Y., and A.K. are employees of Analysis Group, Inc., which has received funding from GSK to conduct the study. A.M., A.V.J., S.J., and F.S.M-G. are employees of and shareholders in GSK. Aspects of this work were previously presented at ECCMID 2022 in the form of posters and summary slides. These were entitled: “Antimicrobial Resistance Patterns and Patient Characteristics Among Females With Uncomplicated Urinary Tract Infection in Germany: A Physician-Based Chart Review” and “Treatment Patterns and Outcomes in Female Outpatients With Uncomplicated Urinary Tract Infection in Germany: A Physician-Based Chart Review”.